Blue Review
A newsletter for contracting institutional and professional providers

May 2021

Fighting Fraud, Waste and Abuse: Ketamine Infusion Therapy

The Blue Cross and Blue Shield of Illinois (BCBSIL) Special Investigations Department (SID) has become aware of several cases involving experimental, investigational, and/or unproven intravenous ketamine infusions to treat chronic pain and psychiatric disorders.

The BCBSIL medical policy for intravenous anesthetics for the treatment of pain and psychiatric disorders (SUR702.016) provides specific guidelines surrounding the intravenous infusion of anesthetics (e.g., ketamine or lidocaine) for the treatment of chronic pain and psychiatric disorders. BCBSIL independently contracted providers are encouraged to review this information to help ensure they are submitting claims that are in alignment with the policy.

If you are aware of an instance of potential fraud, we encourage you to file a report online or call BCBSIL at 877-272-9741 to make a report. All online reports and calls are confidential, and you may remain anonymous.

To view the medical policy for intravenous anesthetics for the treatment of pain and psychiatric disorders, and access the most up-to-date BCBSIL Medical Policy information, refer to the Medical Policy section of our Provider website. Although medical policies can be used as a guide, providers serving HMO members should refer to the HMO Scope of Benefits in the BCBSIL Provider Manual.